One of the research interests in our lab is focused on the deep-molecular characterization of a clinically well-defined cohort of patients anchored in genomic data. Alzheimer’s (AD) and Parkinson’s disease (PD) are heterogeneous disorders with identifiable clinical-pathological subtypes based on symptom severity and predominance. An accurate molecular profile could reduce clinical heterogeneity among AD and PD patients. Our laboratory uses high-throughput and hypothesis-free “omics” technologies to address this important translational aspect, including next-generation DNA sequencing, epigenomics, transcriptomics, proteomics, metabolomics, and lipidomics, to generate a highly detailed molecular atlas for AD and PD. We aim to create a framework for uncovering proteins, genes, pathways, and potential biomarkers that will improve our understanding of underlying disease mechanisms, predict disease course, and improve the design of clinical trials.
